Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M19-751 Pediatric Ulcerative Colitis Study of Risankizumab
jRCT2061260057Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in autoimmune colitis (6 cohorts), sponsored by AbbVie Inc. Primary endpoints: Cmax, Tmax and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
risankizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2061260057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260057.